Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. the FAST-MI registry

International Journal of Cardiology

Volumn 166, Issue 1, 2013, Pages 106-110

  Puymirat, Etienne ^a   Aïssaoui, Nadia ^a   Collet, Jean Philippe ^b   Chaib, Aurès ^a   Bonnet, Jean Louis ^c   Bataille, Vincent ^d   Drouet, Elodie ^e   Mulak, Geneviève ^f   Ferrières, Jean ^d   Blanchard, Didier ^a   Simon, Tabassome ^e,g   Danchin, Nicolas ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c TIMONE HOSPITAL   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f Societe Francaise de Cardiologie   (France)

^g SORBONNE UNIVERSITÉ   (France)

Author keywords

Acute myocardial infarction; Bleeding; Elderly; Low molecular weight heparin; Unfractioned heparin

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE REGISTRY; DRUG SAFETY; DRUG USE; FEMALE; GERIATRIC PATIENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; PROPENSITY SCORE; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; REGISTRIES; SURVIVAL RATE;

EID: 84877781829     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.10.008     Document Type: Article

References (27)

1. K. Barakat, P. Wilkinson, A. Deaner, D. Fluck, K. Ranjadayalan, and A. Timmis How should age affect management of acute myocardial infarction? A prospective cohort study Lancet 353 1999 955 959
2. S. De Servi, C. Cavallini, and A. Dellavalle Non-ST-elevation acute coronary syndrome in the elderly: treatment strategies and 30-day outcome Am Heart J 147 2004 830 836
3. C.N. Shahi, S.S. Rathore, and Y. Wang Quality of care among elderly patients hospitalized with unstable angina Am Heart J 142 2001 263 270
4. J.P. Cambou, T. Simon, G. Mulak, V. Bataille, N. Danchin for the FAST-MI investigators The French registry of Acute ST elevation or non-ST-elevation Myocardial Infarction (FAST-MI): study design and baseline characteristics Arch Mal Coeur Vaiss 100 2007 524 534
5. A.K. Rao, C. Pratt, and A. Berke Thrombolysis in Myocardial Infarction (TIMI) Trial phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11
6. European Association for Percutaneous Cardiovascular Interventions W. Wijns, and P. Kolh Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 31 2010 2501 2555
7. E.M. Antman, D.A. Morrow, and C.H. McCabe ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354 2006 1477 1488
8. R.W. Yeh, S.D. Wiviott, and R.P. Giugliano Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes Am J Cardiol 100 2007 1734 1738
9. J. Hirsh, T.E. Warkentin, R. Raschke, C. Granger, E.M. Ohman, and J.E. Dalen Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety Chest 114 1998 489S 510S
10. N. Martel, J. Lee, and P.S. Wells Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis Blood 106 2005 2710 2715
11. E. Nikolsky, H.M. Sadeghi, and M.B. Effron Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction Am J Cardiol 96 2005 474 481
12. M. Cohen, C. Demers, and E.P. Gurfinkel A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group N Engl J Med 337 1997 447 452
13. G.C. Wong, R.P. Giugliano, and E.M. Antman Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention JAMA 289 2003 331 342
14. R.M. Califf, J.L. Petersen, V. Hasselblad, K.W. Mahaffey, and J.J. Ferguson A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes Am Heart J 149 2005 S91 S99
15. M. Cohen The role of low-molecular-weight heparin in the management of acute coronary syndromes J Am Coll Cardiol 41 2003 55S 61S
16. E.M. Antman, C.H. McCabe, and E.P. Gurfinkel Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial Circulation 100 1999 1593 1601
17. E.M. Antman, M. Cohen, C. McCabe, S.G. Goodman, S.A. Murphy, and E. Braunwald TIMI 11B and ESSENCE Investigators. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE Eur Heart J 23 2002 308 314
18. M. Cohen, C. Demers, and E.P. Gurfinkel Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin,in non-Q-wave Coronary Events Am J Cardiol 82 1998 19L 24L
19. M. Cohen, P. Théroux, and S. Borzak Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin Am Heart J 144 2002 470 477
20. D.H. Fitchett, A. Langer, P.W. Armstrong, M. Tan, A. Mendelsohn, and S.G. Goodman INTERACT Trial Long-Term Follow-Up Investigators. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial Am Heart J 151 2006 373 379
21. K.W. Mahaffey, and J.J. Ferguson Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial Am Heart J 149 2005 S81 S90
22. U. Zeymer, A. Gitt, and C. Jünger Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice Am J Cardiol 98 2006 19 22
23. R.D. Lopes, K.P. Alexander, and G. Marcucci Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial Eur Heart J 29 2008 1827 1833
24. F.G. Kushner, M. Hand, and S.C. Smith Jr. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
25. G. De Luca, and P. Marino Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials Am Heart J 154 2007 1085.e1 1085.e6
26. G. Montalescot ATOLL: an international, randomized trial comparing i.v. enoxaparin with i.v. unfractionated heparin in primary PCI for ST-elevation myocardial infarction. ESC congress 2010 http://www.escardio.org/congresses/esc- 2010/congress-reports/Pages/707-4-ATOLL.aspx (31 december 2010)
27. P.R. Sinnaeve, Y. Huang, and K. Bogaerts ASSENT-3 and ASSENT-3 PLUS investigators. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS Am Heart J 152 2006 684.e1 684.e9